
Diego A. Díaz García
@diegoadiazg
Medical Oncologist | Fellow in Thoracic Oncology @incanMX / CánCare • Hospital Ángeles del Carmen / Opinions my own
ID: 229303152
http://cancare.com.mx 22-12-2010 02:09:20
1,1K Tweet
1,1K Followers
1,1K Following

🫁 Evolving roles of MET as a therapeutic target in NSCLC and beyond. 🔹 MET alterations are reshaping the therapeutic landscape in NSCLC. 🔹 MET TKIs, antibodies, and ADCs (like telisotuzumab vedotin, FDA-approved May 2025) are expanding treatment options. 📖 NatureRevClinOncol
